Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PSTV 
Plus Therapeutics Inc (PSTV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PSTV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -62.65% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.01M USD | Price to earnings Ratio - | 1Y Target Price 9.38 |
Price to earnings Ratio - | 1Y Target Price 9.38 | ||
Volume (30-day avg) 32553598 | Beta 0.73 | 52 Weeks Range 0.24 - 2.67 | Updated Date 04/1/2025 |
52 Weeks Range 0.24 - 2.67 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-03 | When Before Market | Estimate -0.4967 | Actual -0.49 |
Profitability
Profit Margin -225.07% | Operating Margin (TTM) -260.92% |
Management Effectiveness
Return on Assets (TTM) -90.42% | Return on Equity (TTM) -522.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5775259 | Price to Sales(TTM) 1.05 |
Enterprise Value 5775259 | Price to Sales(TTM) 1.05 | ||
Enterprise Value to Revenue 18.19 | Enterprise Value to EBITDA -0.3 | Shares Outstanding 5896330 | Shares Floating 5870920 |
Shares Outstanding 5896330 | Shares Floating 5870920 | ||
Percent Insiders 17.36 | Percent Institutions 11.5 |
Analyst Ratings
Rating 4.5 | Target Price 15.75 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Plus Therapeutics Inc
Company Overview
History and Background
Plus Therapeutics, Inc. was founded in 1996 as Cytoclonal Pharmaceutics, Inc. and later changed its name. It focuses on developing targeted radiotherapeutics for cancer using its liposomal platform. The company has evolved through various clinical trials and strategic partnerships.
Core Business Areas
- Radiotherapeutic Development: Develops and commercializes targeted radiotherapeutics using a liposomal delivery system.
- ReSPECT-LM: ReSPECT-LM is their lead drug candidate using Rhenium-186 Nanoliposome for recurrent glioblastoma (GBM) and other cancers.
Leadership and Structure
Marc Hedrick is the current President and CEO. The company has a board of directors and an executive team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- ReSPECT-LM: ReSPECT-LM is the lead drug candidate for recurrent glioblastoma (GBM). Market share is currently negligible as it is still in clinical trials. Competitors include standard of care treatments like surgery, radiation, and chemotherapy, as well as targeted therapies from companies like Novocure (NVCR) with Optune.
Market Dynamics
Industry Overview
The radiopharmaceutical market is growing due to advancements in targeted therapies and imaging techniques. Demand is driven by the need for more effective cancer treatments.
Positioning
Plus Therapeutics is positioned as a developer of targeted radiotherapeutics. Its competitive advantage lies in its liposomal delivery system, which aims to improve drug delivery and reduce side effects.
Total Addressable Market (TAM)
The global radiopharmaceuticals market is expected to reach billions of dollars. Plus Therapeutics aims to capture a portion of this market with ReSPECT-LM and other potential products. TAM is $7.1B in 2024, expected to grow to $11.1B by 2029. Plus Therapeutics seeks to address unmet needs in the GBM market which is part of this wider TAM.
Upturn SWOT Analysis
Strengths
- Novel liposomal delivery system
- Targeted radiotherapeutic approach
- Potential for improved efficacy and safety
- Focus on unmet medical needs
Weaknesses
- Early-stage clinical development
- Limited financial resources
- High regulatory hurdles
- Dependence on successful clinical trial outcomes
Opportunities
- Successful completion of clinical trials
- Partnerships with larger pharmaceutical companies
- Expansion to other cancer indications
- Growing radiopharmaceutical market
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory setbacks
- Funding challenges
Competitors and Market Share
Key Competitors
- NVCR
- MRK
- BMY
Competitive Landscape
Plus Therapeutics competes with companies offering standard of care treatments and novel therapies for cancer. Its liposomal delivery system offers a potential competitive advantage but needs to demonstrate clinical superiority.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been limited as the company focuses on R&D. Potential for future growth is tied to the success of ReSPECT-LM and other pipeline candidates.
Future Projections: Future growth projections depend on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary based on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include advancing ReSPECT-LM through clinical trials and seeking partnerships.
Summary
Plus Therapeutics is a development-stage company focused on targeted radiotherapeutics. Their ReSPECT-LM shows promise, but its clinical success is critical. The company faces financial challenges and competition, so careful management and successful trials are crucial for the company's survival.
Similar Companies
NVCR
Novocure Ltd
NVCR
Novocure Ltd
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary. Financial data may not be up to date. Future results are not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Plus Therapeutics Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2000-11-16 | President, CEO & Director Dr. Marc H. Hedrick M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://plustherapeutics.com |
Full time employees 20 | Website https://plustherapeutics.com | ||
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.